Skip to main content

Table 1 BAL/serum cytokine concentrations (pg/mL) in RSV infected mice treated with motavizumab compared with untreated RSV infected controls on day 1 after inoculation. Each group consisted of 4 samples randomly selected from two independent experiments.

From: Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model

  BAL (D1)   SERUM (D1)  
  RSV Untreated RSV Motavizumab p value RSV Untreated RSV motavizumab p value
IFN-γ 67.16 ± (24.6) 28.01 ± (13.8) 0.03 ND ND ---
MCP-1 1930.68 ± (716.6) 1088.12 ± (307.8) 0.07 381.83 (341.0–554.8) 230.65 (217.43–298.83) 0.6
RANTES 1952.10 ± (999.05) 671.66 ± (340.4) 0.051 ND ND ---
IL-10 39.29 ± (27.0) 14.47 ± (7.8) 0.1 102.23 ± (22.5) 16.78 ± (13.56) 0.001
TNF-α 2290.90 ± (1100.2) 279.03 ± (204.7) 0.01 ND ND ---
GM-CSF 101.42 (45.7–144.9) 25.14 (22.1–34.0) 0.1 ND ND ---
IL-12p70 44.14 ± (13.5) 22.59 ± (8.7) 0.03 45.85 ± (17.5) 23.75 ± (16.1) 0.16
KC 3967.43 (2039.8–5795.3) 1303.57 (946.4–1657.1) 0.1 215.86 ± (125.8) 37.63 ± (32.5) 0.03
IL-6 2580.89 ± (1413.6) 821.79 ± (290.13) 0.051 91.39 (45.43–135.31) 31.17 (18.97–35.85) 0.2
IL-1β 477.52 (231.53–831.92) 182.78 (179.4–214.3) 0.3 266.88 ± (74.4) 119.70 ± (143.5) 0.16
IL-1α 289.75 ± (114.0) 76.28 ± (29.1) 0.01 ND ND ---
IL-17 ND ND --- 20.68 (11.94–31.85) 10.67 (10.06–12.03) 0.2
  1. Note: Data are shown as mean ± SD, or medians and 25–75% range as appropriate according to whether they were normally distributed. ND (non-detected)